Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

Regeneron is now poised to step in and purchase this customer data, for $256 million.The sale includes 23andMe’s customer-facing genomics service arm, as well as its health and research arm.

After the company filed for bankruptcy in March, this week, the sale of 23andMe was completed after previously being approved by a judge.

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron founder, chairman and CEO Dr. Leonard Schleifer joins 'Squawk Box' to discuss the company's bid for 23andMe, privacy concerns over 23andMe's genetic data, importance of biotechnology ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in ...

23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened. Back to Top Albany Business Review ...

The case came after New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase 23andMe in a $256 million deal. That deal has since faced new challenges in ...

According to 23andMe's policy, deletion requests are still being accepted. "Find a secure way to download that data first, because that is, in fact, your own intellectual property," Carter said.

Wojcicki and biotech company Regeneron are the final two bidders, ... The final round of bidding will occur later this week. “23andMe remains committed to protecting customer data.